Navigation Links
PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year

Third Quarter Highlights - Gross new authorizations of $570.6 million, a sequential increase of 20.6

percent, resulting in a net book-to-bill ratio of 1.4 - Cash flow from operations of $61.6 million, resulting in $146.3 million

cash flow from operations year-to-date

- EPS of $0.32 within guidance range

WILMINGTON, N.C., Oct. 23 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today reported its financial and operating results for the third quarter ended September 30, 2007.

PPD recorded net revenue of $357.2 million for the third quarter of 2007, an increase of 14.1 percent over net revenue of $313.1 million for the third quarter of 2006. Net revenue for the third quarter 2007 included reimbursed out-of-pocket expenses of $28.7 million, compared to $23.3 million for the same period in 2006.

Income from operations for third quarter 2007 was $52.9 million, compared to income from operations of $52.0 million for the same period last year. Third quarter 2007 income from operations included $4.3 million of stock compensation expense, compared to stock compensation expense of $5.0 million for the third quarter 2006. Research and development expense for third quarter 2007 was $8.4 million, compared to $1.9 million for the same period last year. The increase in R&D expense was primarily related to costs incurred to conduct Phase I clinical studies for PPD's statin compound for the treatment of dyslipidemia.

Third quarter 2007 earnings per diluted share were $0.32, compared to earnings per diluted share of $0.31 for the third quarter of 2006.

Segment Performance

Development segment net revenue for third quarter 2007, which does not include reimbursed out-of-pocket expenses, was $323.8 million, an increase of 13.5 percent over the same period in 2006. Development segment income from operations for third quarter 2007 was up 14.0 percent to $61.2 million from $53.6 million for the same period in 2006.

Discovery sciences segment net revenue, which does not include reimbursed out-of-pocket expenses, was $4.7 million for the third quarter of 2007, compared to $4.5 million in the same period last year. Discovery sciences segment third quarter 2007 loss from operations was $8.3 million, compared to a loss from operations of $1.7 million for the third quarter 2006. The third quarter 2007 loss from operations reflects the impact of increased R&D expense to further develop the statin compound.

Other Financial Information

Gross new business authorizations for the third quarter of 2007 totaled $570.6 million. The third quarter 2007 cancellation rate was 21.8 percent. Year-to-date net days sales outstanding (DSO) at September 30, 2007, were 49.1 days, compared to year-to-date DSO of 44.0 at December 31, 2006. Third quarter 2007 cash flow from operations was $61.6 million. At September 30, 2007, PPD had $444.2 million in cash, cash equivalents and short-term investments.

Cash Dividend Policy

PPD also announced its board of directors has amended the annual cash dividend policy to increase the annual dividend rate from $0.12 to $0.40 per year, payable quarterly at a rate of $0.10 per share. PPD expects the new dividend rate will be effective beginning in the fourth quarter 2007.

"Another period of strong proposal flow in the third quarter 2007 combined with an improved hit rate helped fuel a 21 percent sequential increase in gross authorizations for the quarter," said Fred Eshelman, chief executive officer of PPD. "We were pleased to announce the addition of three new members of our management team and the realignment of our regional clinical operations teams, and we plan to continue our focus on core business execution."

Eshelman added, "PPD's board of directors, management team and employees are pleased to be able to reward our shareholders through the substantial increase in our annual cash dividend rate, and we remain firmly committed to unlocking additional shareholder value through the delivery of high quality services and the advancement of our compound portfolio strategy."

PPD will conduct a live conference call and audio webcast tomorrow, October 24, 2007, at 9 a.m. ET to discuss its third quarter 2007 results. A Q&A session will follow. To access the webcast, please visit and follow the instructions under the Investor Presentations/Webcasts link in the Corporate section of the Web site. A replay of the webcast will be available shortly after the call. PPD has established a direct dial number, +877 644 0692 (Conference ID: 18887347), for telephone access.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about company growth, the prospects of the compound partnering business and the payment of future dividends under the annual cash dividend policy, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward- looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: success in sales growth; loss of large contracts; increased cancellation rates; risks that we may not continue our annual cash dividend policy; the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.


Steve Smith (Investors)

+910 558 7585

Louise Caudle (Media)

+919 462 4467

PPD, Inc.

Statement of Operations Data

(in thousands, except per share amounts)


Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Net revenue:

Development $323,769 $285,348 $940,452 $821,987

Discovery Sciences 4,694 4,456 13,577 27,955

Reimbursed out-of-pockets 28,732 23,344 85,388 71,528

Total net revenue 357,195 313,148 1,039,417 921,470

Direct costs:

Development 163,221 144,121 472,651 412,560

Discovery Sciences 2,775 2,416 7,595 6,893

Reimbursable out-of-pocket

expenses 28,732 23,344 85,388 71,528

Total direct costs 194,728 169,881 565,634 490,981

Research and development 8,353 1,887 14,221 3,829

Selling, general and

administrative 87,129 77,289 245,016 229,906

Depreciation 14,057 12,008 40,330 34,317

Amortization 78 84 234 481

Income from operations 52,850 51,999 173,982 161,956

Other income, net 4,224 3,778 12,798 11,258

Income before income taxes 57,074 55,777 186,780 173,214

Income tax expense 18,834 18,964 63,906 58,141

Net income $38,240 $36,813 $122,874 $115,073

Net income per share:

Basic $0.32 $0.31 $1.04 $0.99

Diluted $0.32 $0.31 $1.03 $0.97

Weighted average number of

shares outstanding:

Basic 118,739 116,971 118,297 116,608

Diluted 120,065 118,791 119,759 118,399

PPD, Inc.

Balance Sheet Data

(in thousands)


September 30, December 31,

2007 2006

Cash, cash equivalents and short-term

investments $444,177 $435,671

Accounts receivable and unbilled

services, net $468,715 $408,917

Working capital $559,423 $412,711

Total assets $1,617,103 $1,481,565

Unearned income $191,072 $195,707

Current maturities of long-term debt $6 $75,159

Shareholders' equity $1,109,492 $952,900

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... England , November 26, 2015 ... medical device company specializing in imaging technologies, announced today that ... Commission as part of the Horizon 2020 European Union Framework ... out a large-scale clinical trial in breast cancer. ... , --> --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):